One of the possible causes for the supply drought is the shaky test-to-treat initiative, which faces fewer COVID-19 tests and a public wary of taking a new medication.
The GoodRx study also revealed an even distribution of Paxlovid to racial minorities in urban areas, including Black, Hispanic, Asian and Native American populations.
To determine how Paxlovid was distributed, GoodRx used HHS data detailing the number of publicly available Paxlovid courses distributed by county.
After gaining FDA approval and being available at the end of 2021, Paxlovid recently surpassed other antiviral treatments. In clinical trials, the Pfizer drug had an 89 percent efficacy rate in reducing the risk of hospitalization or death in adults.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.